Ustekinumab is associated with superior effectiveness outcomes compared to vedolizumab in Crohn’s disease patients with prior failure to anti‐TNF treatment
Alimentary Pharmacology & Therapeutics2020Vol. 52(1), pp. 123–134
Citations Over TimeTop 1% of 2020 papers
Vince Biemans, C. Janneke van der Woude, Gerard Dijkstra, Andrea E. van der Meulen‐de Jong, Mark Löwenberg, Nanne K.H. de Boer, Bas Oldenburg, Nidhi Srivastava, Jeroen M. Jansen, Alexander Bodelier, Rachel West, Annemarie C. de Vries, J Haans, Dirk de Jong, Frank Hoentjen, Marieke Pierik, the Dutch Initiative on Crohn and Colitis (ICC)
Abstract
Ustekinumab was associated with superior effectiveness outcomes when compared to vedolizumab, while safety outcomes were comparable after 52 weeks of treatment in CD patients who have failed anti-TNF treatment.
Related Papers
- → Review article: predictors of response to vedolizumab and ustekinumab in inflammatory bowel disease(2018)129 cited
- → Ustekinumab and vedolizumab for extraintestinal manifestations in inflammatory bowel disease - a retrospective study(2022)11 cited
- → Letter: potential selection bias in the real‐world comparison of ustekinumab versus vedolizumab as a second‐line treatment for Crohn’s disease(2022)1 cited
- → P386 Two year follow up of children with Inflammatory Bowel Disease (IBD) treated with vedolizumab and ustekinumab(2021)
- → P688 Comparative Effectiveness of Ustekinumab Versus Vedolizumab in Treating Crohn’s Disease After Failure of Anti-TNF Agents: Real-World Evidence(2024)